156 related articles for article (PubMed ID: 24309225)
1. Warning letters to sponsor-investigators at academic health centres - the regulatory "canaries in a coal mine".
O'Reilly EK; Blair Holbein ME; Berglund JP; Parrish AB; Roth MT; Burnett BK
Clin Invest Med; 2013 Dec; 36(6):E290-6. PubMed ID: 24309225
[TBL] [Abstract][Full Text] [Related]
2. A study of warning letters issued to institutional review boards by the United States Food and Drug Administration.
Bramstedt KA; Kassimatis K
Clin Invest Med; 2004 Dec; 27(6):316-23. PubMed ID: 15675112
[TBL] [Abstract][Full Text] [Related]
3. A Retrospective Analysis of Clinical Research Misconduct Using FDA-Issued Warning Letters and Clinical Investigator Inspection List From 2010 to 2014.
Romano CA; Nair S; Delphin ES
Anesth Analg; 2018 Mar; 126(3):976-982. PubMed ID: 29239950
[TBL] [Abstract][Full Text] [Related]
4. A study of warning letters issued to clinical investigators by the United States Food and Drug Administration.
Bramstedt KA
Clin Invest Med; 2004 Jun; 27(3):129-34. PubMed ID: 15305804
[TBL] [Abstract][Full Text] [Related]
5. Analysis of warning letters issued by the US Food and Drug Administration to clinical investigators, institutional review boards and sponsors: a retrospective study.
Shetty YC; Saiyed AA
J Med Ethics; 2015 May; 41(5):398-403. PubMed ID: 24965716
[TBL] [Abstract][Full Text] [Related]
6. An audit of US FDA warning letters issued to sponsors, institutional review boards and investigators over a six-year period.
Saxena U; Bose D; Saha S; Gogtay NJ; Thatte UM
Indian J Med Ethics; 2022; VII(2):108-113. PubMed ID: 35765256
[TBL] [Abstract][Full Text] [Related]
7. Research Misconduct in FDA-Regulated Clinical Trials: A Cross-sectional Analysis of Warning Letters and Disqualification Proceedings.
Garmendia CA; Bhansali N; Madhivanan P
Ther Innov Regul Sci; 2018 Sep; 52(5):592-605. PubMed ID: 29714564
[TBL] [Abstract][Full Text] [Related]
8. A study of warning letters issued to clinical investigators and institutional review boards by the United States Food and Drug Administration.
Gogtay NJ; Doshi BM; Kannan S; Thatte U
Indian J Med Ethics; 2011; 8(4):211-4. PubMed ID: 22106658
[TBL] [Abstract][Full Text] [Related]
9. Data Integrity in the Pharmaceutical Industry: Analysis of Inspections and Warning Letters Issued by the Bioresearch Monitoring Program Between Fiscal Years 2007-2018.
Rogers CA; Ahearn JD; Bartlett MG
Ther Innov Regul Sci; 2020 Sep; 54(5):1123-1133. PubMed ID: 32096103
[TBL] [Abstract][Full Text] [Related]
10. Content Analysis of 2012-2019 FDA Warning Letters and Notices of Violations using the Economic, Clinical, and Humanistic Outcomes (ECHO) Model.
Mohite N; Funtanilla V; Muzumdar J; Park T
Innov Pharm; 2021; 12(1):. PubMed ID: 34007685
[TBL] [Abstract][Full Text] [Related]
11. An Updated Review of Food and Drug Administration Warning and Untitled Letters for Clinical Outcome Assessment Claims Between 2013 and 2021.
Sams L; Slagle AF; Symonds T; Antonova J; Globe D
Value Health; 2023 Dec; 26(12):1675-1680. PubMed ID: 37748736
[TBL] [Abstract][Full Text] [Related]
12. Analysis of FDA Warning Letters Issued to Indian Pharmaceutical and Medical Device Companies: A Retrospective Study.
Bablani S; Janodia MD
Ther Innov Regul Sci; 2020 Jul; 54(4):925-931. PubMed ID: 32557315
[TBL] [Abstract][Full Text] [Related]
13. A review of FDA warning letters and notices of violation issued for patient-reported outcomes promotional claims between 2006 and 2012.
Symonds T; Hackford C; Abraham L
Value Health; 2014 Jun; 17(4):433-7. PubMed ID: 24969004
[TBL] [Abstract][Full Text] [Related]
14. An FDA Analysis of Inspected Entities After Receiving Official Action Indicated Letters for Good Clinical Practice Violations.
Jung M; Swann RM; Anantha MS; Jamali F
Ther Innov Regul Sci; 2021 Sep; 55(5):907-917. PubMed ID: 34101151
[TBL] [Abstract][Full Text] [Related]
15. Over-the-Counter Drugs: Regulatory Analysis of Warning Letters Between Fiscal Years 2015-2019.
Bai HK; Ahearn JD; Bartlett MG
Ther Innov Regul Sci; 2021 Mar; 55(2):426-436. PubMed ID: 33095420
[TBL] [Abstract][Full Text] [Related]
16. Health Claims About Cannabidiol Products: A Retrospective Analysis of U.S. Food and Drug Administration Warning Letters from 2015 to 2019.
Wagoner KG; Lazard AJ; Romero-Sandoval EA; Reboussin BA
Cannabis Cannabinoid Res; 2021 Dec; 6(6):559-563. PubMed ID: 34142863
[No Abstract] [Full Text] [Related]
17. Content Analysis of US FDA Warning Letters Issued to Compounding Pharmacies Regarding Violations of Current Good Manufacturing Practices Between 2017 and 2022.
Dmour I
J Pharm Innov; 2022 Nov; ():1-15. PubMed ID: 36407089
[TBL] [Abstract][Full Text] [Related]
18. Unicorn Poo and Blessed Waters: COVID-19 Quackery and FDA Warning Letters.
Bramstedt KA
Ther Innov Regul Sci; 2021 Jan; 55(1):239-244. PubMed ID: 33001378
[TBL] [Abstract][Full Text] [Related]
19. Analysis of US Food and Drug Administration Warning Letters: False Promotional Claims Relating to Prescription and Over-the-Counter Medications.
Salas M; Martin M; Pisu M; McCall E; Zuluaga A; Glasser SP
Pharmaceut Med; 2008 Mar; 22(2):. PubMed ID: 24353430
[TBL] [Abstract][Full Text] [Related]
20. FDA actions against health economic promotions, 2002-2011.
Neumann PJ; Bliss SK
Value Health; 2012; 15(6):948-53. PubMed ID: 22999146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
